全球微小残留病市场 – 行业趋势及 2028 年预测

市场分析与洞察：全球微小残留病市场

预计微小残留疾病市场在 2021 年至 2028 年的预测期内将以 7.90% 的潜在率实现市场增长率。癌症患者数量的增加是推动市场增长的重要因素。

微小残留病灶是指在治疗过程中和治疗后，白血病细胞仍残留在患者体内的一种疾病。现有的癌症治疗程序，即放疗或化疗，无法从患者体内清除所有致癌细胞。

政府对疾病的宣传计划的增加将促进市场增长，疾病患病率的上升、美国医疗保健负担能力的提高以及人们知识和意识的提高是推动微小残留疾病市场增长的一些关键因素。此外，个性化治疗药物的增加、市场研发活动的增加以及产品开发合作的增加将进一步为 2021-2028 年预测期内的微小残留疾病市场创造新的机会。

然而，市场研发活动成本的上升是制约市场的主要因素，并将在上述预测期内进一步挑战微小残留疾病市场。

Minimal residual disease market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the minimal residual disease market scenario contact Data bridge market research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Minimal Residual Disease Market Scope and Market Size

Minimal residual disease market is segmented on the basis of test technique, detection target, test type and end-user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of test technique, minimal residual disease market is segmented into PCR, FISH and NGS.
• Based on detection target, the minimal residual disease market is segmented into leukemia, lymphoma, solid tumors and other.
• Based on test type, the minimal residual disease market is segmented into DNA-based test, RNA-based test and immunological test.
• Minimal residual disease market is also segmented on the basis of end-user into hospitals, laboratory centers and specialty clinics.

Minimal Residual Disease Market Country Level Analysis

Minimal residual disease market is analysed and market size information is provided by country, test technique, detection target, test type and end-user as referenced above.

The countries covered in the minimal residual disease market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

North America dominates the minimal residual disease market due to rise in the prevalence of the disease, rise in the healthcare affordability in the US and rise in the knowledge and awareness amongst the people in this region. Asia-Pacific is the expected region in terms of growth in minimal residual disease market due to rise in the prevalence of cancer in this region.

微小残留疾病市场报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。新销售、替代销售、国家人口统计、疾病流行病学和进出口关税等数据点是用于预测各个国家市场情景的一些主要指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀少竞争而面临的挑战、销售渠道的影响。

患者流行病学分析

微小残留疾病市场还为您提供详细的市场分析，用于患者分析、预后和治疗。患病率、发病率、死亡率、依从率是报告中提供的一些数据变量。分析流行病学对市场增长的直接或间接影响，以创建更稳健、更队列的多元统计模型，用于预测增长期的市场。

竞争格局和微小残留病市场份额分析

微小残留病市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、公司优势和劣势、产品发布、临床试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对微小残留病市场的关注有关。

微小残留病市场报告中涉及的主要参与者包括 Adaptive Biotechnologies、Proteus Digital Health, Inc、Bristol-Myers Squibb Company、Navidea Biopharmaceuticals, Inc、Gilead Sciences, Inc、iRepertoire, Inc、Macrogen 和 Natera, Inc 以及其他国内和全球参与者。微小残留病市场份额数据分别针对全球、北美、南美、欧洲、亚太地区 (APAC) 和中东及非洲 (MEA) 提供。DBMR 分析师了解竞争优势并为每个竞争对手分别提供竞争分析。

SKU-63486